Showing 1501-1510 of 1655 results for "".
- Oxurion Issues Financial and Business Updatehttps://modernod.com/news/oxurion-issues-financial-and-business-update/2476562/Oxurion NV issued a business and a financial update for the 3 months ending March 31, 2019. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly DME. The Oxurion clinical development pipeline consists of novel products wit
- PECAA Community Raises $116,000 for Optometry Giving Sighthttps://modernod.com/news/pecaa-community-raises-116000-for-optometry-giving-sight/2476452/PECAA, a nationwide doctor alliance group for independent eye care professionals, announced in March that through its Growing Through Giving Program, $116,000 had been raised in 2018 for the organization’s charity of
- Iridex Provides Update on World Glaucoma Congress Activitieshttps://modernod.com/news/iridex-provides-update-on-world-glaucoma-congress-activities/2476427/Iridex announced that its Cyclo G6 glaucoma laser and proprietary MicroPulse Technology were featured in various posters and presentations at the World Glaucoma Congress last week in Melbourne, Australia. The congress ran from March 27- 31, 2019. Eight glaucoma specialists provided hands-o
- Arkansas Secures Expanded Scope of Practicehttps://modernod.com/news/arkansas-secures-expanded-scope-of-practice/2479581/As advocates nationwide work to advance optometry’s future-focused role in health care, Arkansas becomes the latest state enacting scope of practice expansion to include surgical procedures, according to the American Optometric Association. Signed into law March 27 by Gov. Asa Hutch
- Optovue Launches New AngioWellness Scan at Vision Expo Easthttps://modernod.com/news/optovue-launches-new-angiowellness-scan-at-vision-expo-east/2476399/Optovue will launch its new AngioWellness scan at Vision Expo East in New York, March 21-24, 2019. The AngioWellness scan utilizes Optovue’s advanced AngioVue OCTA technology to quickly assess and diagnose new pathologies in patients, including diabetic patients and those who may be at ris
- GenSight Biologics to Present 72-Week Data From the REVERSE Phase 3 Trial of GS010https://modernod.com/news/gensight-biologics-to-present-72-week-data-from-the-reverse-phase-3-trial-of-gs010/2476389/GenSight Biologics announced that the 72-week results from the REVERSE Phase 3 clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), which will be held in Las Vegas from March 16 to 21, 2019. The results will be presented b
- Allergan to Present New Data on Bimatoprost SR at the American Glaucoma Society Annual Meetinghttps://modernod.com/news/allergan-to-present-new-data-on-bimatoprost-sr-at-the-american-glaucoma-society-annual-meeting/2476377/Allergan will present new data, including a late-breaking abstract, for Bimatoprost SR at the American Glaucoma Society (AGS) meeting in San Francisco. The abstract, to be presented for the first time on March 16, is
- Eyecare Services Partners Names New CEO and Adds Two Other Executiveshttps://modernod.com/news/eyecare-services-partners-names-new-ceo-and-adds-two-other-executives/2476353/Eyecare Services Partners (ESP) has appointed George Neal as chief executive officer, effective March 4. Mr. Neal was previously chief executive officer of Access Dental, a dental services organization that was recently sold by Guardian Life Insurance Company of America, according to a
- Envision Conference to Split in Two in 2019https://modernod.com/news/envision-conference-to-split-in-two-in-2019/2479634/For the first time since its inception in 2006, Envision Conference will be split into two events for the upcoming year: Envision Conference East, March 22-23, 2019 at the University of Alabama at Birmingham in Birmingham, Alabama; and Envision Conference West, October 5-6, 2019 at the College of
- Marc Bloomensteinhttps://modernod.com/profiles/marc-bloomenstein/LxAAZq/